Centrally acting (moxonidine) and peripherally acting (metoprolol) sympatholytic agents might have different actions upon penile circulation in hypertensive men with erectile dysfunction. A total of 11 nonsmoking, hypertensive but otherwise healthy men with erectile dysfunction were studied after 8 weeks on moxonidine monotherapy (0.4 mg per day, increased to 0.6 mg if needed) and then after 8 weeks of metoprolol monotherapy (100 mg per day, increased to 200 mg if needed) in a crossover design. At the end of each treatment phase, the subjects were asked about their subjective erectile capacity (nocturnal and coital erections), and resting and stimulated (after intracavernosal injection of a mixture of alprostadil and phentolamine) penile deep artery diameters and systolic peak velocities were measured by color Doppler ultrasonography. There were no significant differences in blood pressure after either therapy. The change from earlier antihypertensive therapy, moxonidine produced significant subjective amelioration of sexual dysfunction in 9/11 of the men (Po0.001), whereas 9/11 returned to impaired dysfunction after crossover to metoprolol treatment. Resting and stimulated deep penile diameters and peak systolic velocities were higher after moxonidine treatment compared with metoprolol (diameters: Po0.004, Po0.0001; velocities: Po0.008, Po0.038). The centrally acting sympatholytic agent moxonidine seems to improve erectile function both subjectively and objectively and has a better effect on penile circulation compared with the peripherally acting sympatholytic agent metoprolol.
Introduction
Problems with erectile function have been a concern in the treatment of hypertension and may influence the choice of treatment regimens and decisions to discontinue drugs. Beta-blockers have been reported to be responsible for erectile dysfunction. [1] [2] [3] There is no data on moxonidine in this respect. Centrally acting (moxonidine) and peripherally acting (metoprolol) sympatholytic agents might have different actions upon penile circulation. We compared the effects of these two sympatholytic agents on erectile function and penile circulation at rest and after stimulation in hypertensive men with erectile dysfunction
Methods
In all, 12 nonsmoking hypertensive men with erectile dysfunction, otherwise healthy, participated in the study, which was approved by the Ethics Committee of the University of Turku. All patients signed an informed consent document before entering the study. One patient was dropped from the study during the first treatment phase because of insufficient blood pressure (BP) control (BP4170/ 110 mmHg).
At the beginning of the study, the participants fulfilled International Index of Erectile Function (IIEF-5) criteria. Serum testosterone was assayed in order to disclose significant hypogonadism. At the end of the treatment phases, the subjects were asked about their subjective erectile capacity (nocturnal and coital erections).
After a short washout period (1-3 days) all patients started moxonidine at 0.2+0.2 mg daily and after 3 weeks the dose was increased to 0.4+0.2 mg if BP was 4160/100 mmHg.
After 8 weeks of treatment, the patients were investigated according to the following schedule: penile deep artery diameter (at two sites, mean of four measurements) and peak systolic velocity (PSV) were measured with Acuson Sequoia color Doppler equipment with an 8 MHz linear probe. Thereafter, penile circulation was stimulated with an intracavernosal injection of a mixture of alprostadil (10 mg) and phentolamine (0.1 mg) and the stimulated PSV was measured during the next 20 min. The stimulated inner diameter of the deep penile arteries was measured 10-15 min after stimulation.
After moxonidine therapy, the patients were crossed over to metoprolol (100 mg o.d.) for 3 weeks and thereafter the dose of metoprolol was increased to 100 mg Â 2 if needed. After 5 weeks, the patients were investigated according to the same protocol as described above.
The sitting BP was measured after 15 min rest, once a week during the study. Mean values of the last three measurements are reported.
Student's paired t-test for parametric data and the w 2 test for categorial data were used. Linear regression analysis was used to investigate the relation between the BP taken just before penile circulation assessment and deep penile artery diameters and velocities. Po0.05 was considered statistically significant.
Results
The mean (7s.d.) IIEF-5 score was 15.8 (78.5). Four of our patients had mild erectile dysfunction with IIEF-5 score Z21 and the rest of our patients had moderate-to-severe erectile dysfunction (IIEF-5 o21). The mean serum testosterone concentration was 13.1 (73.3) nmol/l and the mean age of the patients was 50.5 years (range 41-58 years).
Out of 11 patients, seven were on ACE inhibitor therapy when entering the study, but only two of them had monotherapy. The other five men took an ACE inhibitor in combination with a beta-blocker or thiazide diuretic. One patient was on beta-blocker, two on calcium-blocker and one was without any drug treatment.
The dose antihypertensive was increased in nine of the 11 subjects during moxonidine therapy and in eight of the 11 subjects during metoprolol treatment. Mean BP (7s.d.) during moxonidine therapy was 163.8 (716.0)/96.2 (76.3) mmHg and during metoprolol therapy, 157.8 (719.2)/93.6 (711.1) mmHg (P ¼ NS).
Nine of the 11 men reported subjective improvement in their erectile function during moxonidine therapy, whereas two men reported no difference. The overall improvement was highly significant (Po0.001) compared with previous therapy. On the other hand, 9/11 reported impaired erectile function after metoprolol treatment and this difference was statistically highly significant when compared with moxonidine treatment (Po0.0002, w 2 test) ( Table 1) . Resting and stimulated deep penile diameters were higher after moxonidine therapy compared to the diameters after metoprolol therapy (Po0.004 and Po0.001, respectively). Resting and stimulated deep penile artery velocities were also higher after moxonidine therapy compared to metoprolol (0.008 and Po0.038, respectively) ( Table 2 ). There was no correlation between BP and resting/stimulated deep penile artery diameters or velocities (data not shown).
Discussion
Problems with erectile function can rise a concern in the treatment of hypertension and may influence the choice of treatment regimens and decisions to discontinue drugs. We compared the effects of two sympatholytic agents in hypertensive men with erectile dysfunction using color Doppler ultrasound method. Moxonidine seemed to produce significant subjective improvement in sexual function in the majority of men (9/11), whereas metoprolol resulted in a return to reappraisal of erectile dysfunction. These subjective changes were accompanied by significantly higher resting and stimulated deep penile diameters and PSV values after moxonidine therapy compared to metoprolol.
This pilot study was a open crossover study. For safety and ethical reasons the washout period before either treatment were minimal. On the other hand, the treatment phases (8 weeks) were long enough to show the pure effect of both the drugs on penile circulation.
The use of color Doppler ultrasonography in assessing the penile circulatory parameters includes some problems. The method is strongly dependent Sympatholytic agents and erectile dysfunction J Piha and R Kaaja on the investigators experience and in any case particularly the measurement of inner diameters of arteries is quite nonrepeatable. In addition, the nonerect parameters are sensitive to the patients situation during the investigation. In the present study, we tried to minimize these problems by using experienced investigator (Dr J Piha) and by making the measurements at the same time of the day and in the same room. However, ultrasonography is surely the best noninvasive method to get information on penile circulation after pharmacostimulation. Beta-blockers have been reported to be responsible for erectile dysfunction in many, [1] [2] [3] but not all studies. 4 It has been suggested that this may be because of the change in balance between alpha and beta sympathetic influence, resulting in insufficient antagonism of alpha-1 vasoconstriction. 5 Many of these studies are biased by relatively heterogeneous groups of patients having organic or psychogenic (or both) predisposing factors in addition to drugrelated causes. We tried to minimize these confounding factors and investigated relatively young healthy men having mainly hypertension as a risk factor of vascular disease.
Caverno-occlusive and autonomic dysfunction has been proposed as a new concept in the etiology of erectile dysfunction in young men. 6 Moxonidine is a centrally acting sympatholytic antihypertensive agent, which binds selectively and with high affinity to imidazoline (I1) receptors in the rostral ventrolateral medulla and kidney. 7 It could centrally stabilize autonomic dysfunction (sympathetic overactivity) and let the parasympathetic tone override the sympathetic tone, as needed for initiation of erection. Besides this direct effect on sympathetic tone, in contrast to beta-blockers, moxonidine induces vasodilatation with no change in cardiac output and little change in heart rate and it increases insulin sensitivity in insulin-resistant subjects. 8, 9 Our pilot study shows that centrally acting sympatholytic agent (moxonidine) may have a positive effect on erectile function. It also seemed to increase penile circulation compared to the effect of a beta-blocker (metoprolol). However, the observed difference between the drugs may also be more because of the known vasoconstrictive effect of metoprolol than supportive effect of moxonidine. More studies, for example, comparison between ACE inhibitor and moxonidine, are needed to confirm the potential positive role of centrally acting sympatholytic agents on erectile dysfunction. Sympatholytic agents and erectile dysfunction J Piha and R Kaaja
